Clinical Trials
138 trialsTreating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Eastern Cooperative Oncology Group
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
DIVINE
Mayo Clinic
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
VA STARPORT
VA Office of Research and Development
THUNDER
Cancer Research Antwerp
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
ARCH
University of Colorado, Denver
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
CASPAR
Alliance for Clinical Trials in Oncology
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
NePtune
Hoosier Cancer Research Network
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
STEEL
RTOG Foundation, Inc.
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
CARLHA-2
UNICANCER
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
GREAT
Ipsen
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
HypoElect
German Oncology Center, Cyprus
PCS III
Université de Sherbrooke
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
Astellas Pharma Inc
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
Seattle Institute for Biomedical and Clinical Research
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Xijing Hospital
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
The First Affiliated Hospital of Xiamen University
SAVE
Cancer Research Antwerp
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
Endo Pharmaceuticals
ASSERT
University of British Columbia
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
URONCOR 06-24
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
DART
Canadian Cancer Trials Group
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Luye Pharma Group Ltd.